menu search

Alzheimer's medication: eisai reporting positive data on injectable drug

This segment originally aired on October 26, 2023. eisai has (EISAY) reported positive results in clini...

October 28, 2023, 9:00 am

Biogen and eisai's revised alzheimer's drug works, but safety questions linger

Wall Street analysts say Biogen and eisai could secure Food and Drug Administration approval for their ...

October 26, 2023, 10:35 am

: biogen and eisai release new alzheimer’s drug data that may support wider uptake

eisai plans to apply for FDA approval of subcutaneous Leqembi by early next year. Read Full Story The p...

October 25, 2023, 9:28 pm

eisai presents new leqembi® (lecanemab-irmb) investigational subcutaneous formulation interim study results and clinical improvement data in earlier stages of early alzheimer’s disease from additional

Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patien...

October 25, 2023, 9:26 pm

eisai presents new leqembi® (lecanemab-irmb) investigational subcutaneous formulation interim study results and clinical improvement data in earlier stages of early alzheimer’s disease from additional

Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patien...

October 25, 2023, 9:26 pm

Biogen and eisai release new alzheimer's drug data that may support wider uptake

Biogen Inc. and eisai Co. late Wednesday released new data on their Alzheimer's treatment Leqembi that ...

October 25, 2023, 5:28 pm

Merck (mrk), eisai combo therapy fail two lung cancer studies

Data from both late-stage studies evaluating Merck's (MRK) Keytruda and eisai's Lenvima combination in ...

September 25, 2023, 1:32 pm

Leqembi® intravenous infusion (lecanemab) approved for the treatment of alzheimer’s disease in japan

TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) — eisai Co., Ltd. (Headquarters: Tokyo, C...

September 25, 2023, 5:02 am

Japan approves alzheimer treatment leqembi by eisai and biogen

Japan's eisai said on Monday the country's health ministry had approved its Alzheimer treatment Leqembi...

September 25, 2023, 1:16 am

Merck and eisai say two lung-cancer trials failed to meet their main goals

Merck and Japanese partner eisai said Friday that two late-stage trials of a treatment for a certain ty...

September 22, 2023, 7:31 am

Drugmaker merck says keytruda combination fails in lung cancer trial

Merck said on Friday its cancer immunotherapy Keytruda in combination with partner eisai's drug failed ...

September 22, 2023, 7:09 am

Merck (mrk), eisai to end keytruda-lenvima combo cancer study

With the phase III LEAP-010 study failing to show an overall survival benefit for patients with recurrent or metastatic HNSCC, Merck (MRK) and ...

August 28, 2023, 12:02 pm

Merck and eisai cull late-stage study for head and neck cancer therapy

Merck & Co Inc (NYSE:MRK) and research partner eisai said they are halting a late-stage trial that used...

August 25, 2023, 7:58 am

Merck and eisai say late-stage trial of treatment for head and neck cancer did not meet goals

Merck & Co. Inc. MRK, -1.66% and eisai Co. Ltd. 4523, -1.23% ESAIY, -1.95% said Friday a late-stage tri...

August 25, 2023, 6:52 am

Merck, eisai discontinue late-stage study for cancer therapy

Merck & Co and partner eisai said on Friday they will shut down a late-stage study testing an experimen...

August 25, 2023, 6:47 am

eisai presents latest analysis of lecanemab’s effect on biomarker changes and subcutaneous dosing at the alzheimer’s association international conference (aaic) 2023

Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two underlying pathological hallmarks of Alzheimer’s disease New ...

July 19, 2023, 11:30 pm

Biogen, eli lilly likely to split the alzheimer's drug market, analysts say

Eli Lilly and Co. LLY, -0.52% and Biogen Inc. BIIB, -0.19% are likely to reach an “equitable split” of the Alzheimer's drug market after Lilly on ...

July 18, 2023, 8:39 am

Eli lilly & co study shows alzheimer's drug slows memory decline

Eli Lilly & Co revealed on Monday final results from its Phase 3 clinical study of donanemab at the Alzheimer's Association International Conference i...

July 17, 2023, 1:13 pm

Eli lilly expects fda decision on alzheimer's treatment donanemab by the end of the year

Eli Lilly is racing to market donanemab for Alzheimer's after eisai and Biogen's drug for the disease, ...

July 17, 2023, 10:15 am


Search within

Pages Search Results: